TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

Grant

Date/time Interval

  • December 26, 2018 - December 25, 2023

    • Awarded By

    Total Award Amount

  • 53238.00

    • Direct Costs

  • 40952.00

    • Sponsor Award Id

    • Contributor

  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Louis Nabors M.D.   Investigator